Prostate Cancer | Johann de Bono, MBChB, MSc, PhD

Research To Practice | Oncology Videos

Prostate Cancer Update, Issue 2, 2021 — Part 2: Our most recent one-on-one interview with Professor de Bono featuring emerging research and cases from his practice:

• Current and future management of metastatic castration-resistant prostate cancer (mCRPC); role of PARP inhibition as a therapeutic strategy (0:00)
• Choice of therapy for patients with mCRPC who experience disease progression on second-generation antiandrogen agents (24:25)
• Biology of prostate cancer and spectrum of genetic alterations (28:48)
• Therapeutic approach to mCRPC with a BRCA2 mutation (33:00)
• Genomic testing for patients with prostate cancer (41:33)
• Role of ATM mutations in prostate cancer; prevalence of homologous recombination deficiency-related signatures and implications for therapeutic decision-making (45:05)
• Monitoring and managing side effects associated with PARP inhibitors (51:40)
• Management of CRPC in patients who experience disease progression on secondary hormonal therapy (57:47)
• Design and results from the Phase III PROfound study comparing olaparib to AR-targeted therapy for patients with mCRPC harboring homologous recombination repair gene alterations (1:03:34)
• Efficacy of olaparib in Cohort B (patients with mCRPC with homologous recombination repair gene alterations other than BRCA1/2 or ATM) of the PROfound study (1:07:42)
• Activity of rucaparib monotherapy in patients with mCRPC (1:18:00)
• Results of the Phase III HERO trial evaluating relugolix, an oral GnRH receptor antagonist, versus leuprolide for advanced prostate cancer (1:25:32)

CME information and select publications